STAT
The STAT transcription factors transmit type I/II cytokine signals downstream of the JAKs.There are seven members of the mammalian STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. STAT proteins contain an amino terminal, a coiled coil, a DNA-binding domain (DBD), a linker, a Src-homology2 (SH2), and a transcriptional activation domain (TAD). Inactive cytoplasmic STATs exist primarily as monomers or preformed dimers; upon activation, STAT dimers form a nutcracker-like structure. The highly conserved SH2 domain forms the hinge of this structure and is the target of most patented STAT inhibitors. The linker region and DBD surround the centrally located chromatin like the jaws of the nutcracker, whereas the TAD is located at the C terminus and undergoes serine phosphorylation to recruit additional transcriptional activators and enhance transcriptional activity. These areas display the lowest sequence conservation. Given the involvement of STATs in signaling events downstream of cytokine receptors as well as growth factors, STATs have long been considered as potential therapeutic targets for cancer and autoimmune disease.
References
1.Banerjee S,et al. Drugs. 2017;77(5):521–546.
References
1.Banerjee S,et al. Drugs. 2017;77(5):521–546.
STAT
-
STAT6-IN-2
catalog no : M37229
cas no: 1355594-85-2
STAT6-IN-2 (Comp R-84) is a STAT6 inhibitor that effectively reduces the secretion of the chemokine eotaxin-3, which induces eosinophil infiltration. This compound is valuable for studying immune diseases . -
JI069
catalog no : M37038
cas no: 850019-35-1
JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1. -
Nirsevimab
catalog no : M36818
cas no: 1989556-22-0
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection. -
Suptavumab
catalog no : M36790
cas no: 1629615-23-1
Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system. -
Palivizumab
catalog no : M36768
cas no: 188039-54-5
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).